Comparative Bioavailability of a New Commercial Tablet Formulation and Two Lots of a Reference Formulation of Haloperidol
- 1 June 1989
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 78 (6) , 443-447
- https://doi.org/10.1002/jps.2600780603
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- An Ultrasensitive Method for the Measurement of Haloperidol and Reduced Haloperidol in Plasma by High-Performance Liquid Chromatography with Coulometric DetectionTherapeutic Drug Monitoring, 1988
- HALOPERIDOL METABOLISM AND ANTIPSYCHOTIC EFFECT IN SCHIZOPHRENIAThe Lancet, 1987
- Pharmacokinetics of haloperidol in psychotic patientsPsychopharmacology, 1987
- Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomesBiochemical Pharmacology, 1985
- Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brainNeuropharmacology, 1985
- Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the ratPsychopharmacology, 1984
- Haloperidol kinetics after oral and intravenous dosesClinical Pharmacology & Therapeutics, 1983
- Haloperidol Plasma Level Monitoring in Neuropsychiatric PatientsTherapeutic Drug Monitoring, 1982
- Isolation and Identification of a Metabolite of HaloperidolJournal of Analytical Toxicology, 1981
- Distribution excretion and metabolism of neuroleptics of the butyrophenone type: Part II. Distribution, excretion and metabolism of haloperidol in Sprague-Dawley ratsEuropean Journal of Pharmacology, 1967